International Journal of Hematology and Oncology
2024, Vol 34, Num 4 Page(s): 206-212
| Back | Table of Contents | PDF | Mail to Author | |
Gustave Roussy Immune Score (GRIm-Score) Predicts Prognosis in Non-Small Cell Lung Cancer Patients Undergoing Nivolumab: A Multicenter Retrospective Study from Turkiye
Nargiz MAJIDOVA1, Sedat YILDIRIM2, Erkam KOCAASLAN3, Ali Kaan GUREN3, Hacer Sahika YILDIZ2, Muhammed Fatih KIRCALI3, Mustafa SEYYAR4, Nadiye SEVER3, Nedim TURAN2, Ibrahim Vedat BAYOGLU3
1VM Medical Park Maltepe Hospital, Division of Medical Oncology
2Health Science University, Kartal Dr. Lütf Kirdar City Hospital, Division of Medical Oncology
3Marmara University Faculty of Medicine, Division of Medical Oncology
4Gaziantep City Hospital, Division of Medical Oncology
Keywords: Non-small cell lung cancer, Gustave Roussy Immune Score, Peripheral blood inflammatory markers, Nivolumab, Immunotherapy
The Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker used for predicting the survival outcomes of cancer patients who are undergoing immunotherapy. The purpose of this study is to evaluate the prognostic significance of the GRIm-Score in advanced NSCLC patients treated with nivolumab, and to explore its role in clinical decision-making and treatment optimization. This two-center retrospective study included 285 patients with metastatic NSCLC treated with nivolumab between 2021 and 2024. Clinico-pathologic characteristics, laboratory parameters and treatment responses were evaluated. GRIm-Score was calculated by neutrophil-to-lymphocyte ratio (NLR), baseline albumin and lactate dehydrogenase (LDH) levels. The median age of the patients was 64 years and men were 86.7% of all patients. Compared to those with a high GRIm-Score (2-3), those with a low GRIm-Score (0-1) had significantly better disease control rates (DCR) and objective response rates (ORR) (DCR: 79.7% vs. 32.8%, p= 0.0001; ORR: 56.5% vs. 18.5%; p= 0.0001). In multivariate analysis, serum albumin level, de novo metastatic disease and NLR outcome were predictive of overall survival. Low GRIm-score was associated with long-term survival. The GRIm-Score is an important prognostic factor in patients with advanced NSCLC treated with nivolumab. The GRIm-Score can guide clinicians in selecting patients for nivolumab therapy, optimizing treatment outcomes and resource allocation in clinical practice.
Nargiz MAJIDOVA1, Sedat YILDIRIM2, Erkam KOCAASLAN3, Ali Kaan GUREN3, Hacer Sahika YILDIZ2, Muhammed Fatih KIRCALI3, Mustafa SEYYAR4, Nadiye SEVER3, Nedim TURAN2, Ibrahim Vedat BAYOGLU3
1VM Medical Park Maltepe Hospital, Division of Medical Oncology
2Health Science University, Kartal Dr. Lütf Kirdar City Hospital, Division of Medical Oncology
3Marmara University Faculty of Medicine, Division of Medical Oncology
4Gaziantep City Hospital, Division of Medical Oncology
Keywords: Non-small cell lung cancer, Gustave Roussy Immune Score, Peripheral blood inflammatory markers, Nivolumab, Immunotherapy
The Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker used for predicting the survival outcomes of cancer patients who are undergoing immunotherapy. The purpose of this study is to evaluate the prognostic significance of the GRIm-Score in advanced NSCLC patients treated with nivolumab, and to explore its role in clinical decision-making and treatment optimization. This two-center retrospective study included 285 patients with metastatic NSCLC treated with nivolumab between 2021 and 2024. Clinico-pathologic characteristics, laboratory parameters and treatment responses were evaluated. GRIm-Score was calculated by neutrophil-to-lymphocyte ratio (NLR), baseline albumin and lactate dehydrogenase (LDH) levels. The median age of the patients was 64 years and men were 86.7% of all patients. Compared to those with a high GRIm-Score (2-3), those with a low GRIm-Score (0-1) had significantly better disease control rates (DCR) and objective response rates (ORR) (DCR: 79.7% vs. 32.8%, p= 0.0001; ORR: 56.5% vs. 18.5%; p= 0.0001). In multivariate analysis, serum albumin level, de novo metastatic disease and NLR outcome were predictive of overall survival. Low GRIm-score was associated with long-term survival. The GRIm-Score is an important prognostic factor in patients with advanced NSCLC treated with nivolumab. The GRIm-Score can guide clinicians in selecting patients for nivolumab therapy, optimizing treatment outcomes and resource allocation in clinical practice.
| Back | Table of Contents | PDF | Mail to Author | |